Login to Your Account



ODAC: Study Required To Expand Abraxane's Label

By Aaron Lorenzo


Friday, September 8, 2006
SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Thursday disagreed with a shortened approval pathway for Abraxane (paclitaxel) as an adjuvant breast cancer treatment, which would expand its label. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription